Taro plant doesn't meet GMP requirements, FDA says
Pharma Compliance Alert, February 18, 2009
FDA inspectors found significant deviations from current Good Manufacturing Practices (cGMP) at Taro Pharmaceuticals’ Brampton, Ontario, manufacturing facility, according to an FDA warning letter.
The agency considers the products misbranded because they were not manufactured, processed, packed, and held in compliance with cGMPs. While Taro implemented some corrective actions, the FDA said the company failed to adequately address multiple serious deficiencies.
Related Products
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- Capturing all necessary codes for IUD insertion and removal can be challenging
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- HIPAA Q&A: Level of encryption needed for email
- Case Management Monthly, June 2012
- Searched
